MedTrace Logo

Bioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fasting Conditions

NCT00802828 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2012-03-16

No results posted yet for this study

Summary

Compare the rate and extent of absorption of famotidine 40 mg tablets, administered as 1 x 40 mg tablet under fasting conditions.

Conditions

  • Bioavailability

Interventions

DRUG

Famotidine Tablets, 40 mg

Sponsors & Collaborators

  • Perrigo Company

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2004-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00802828 on ClinicalTrials.gov